The Virtus Biotech ETF seeks to replicate the overall financial performance, encompassing both price appreciation and income generation, of the LifeSci Biotechnology Products Index, prior to any deductions for fees and expenses. This index specifically comprises biotechnology companies that have received approval from the FDA for at least one drug therapy. Furthermore, the fund underwent a name change on February 27, transitioning from Virtus LifeSci Biotech Products ETF to its current designation.

Crinetics Pharmaceuticals, Inc.

Verastem, Inc.

Precigen, Inc.

Iovance Biotherapeutics, Inc.

Omeros Corporation

Halozyme Therapeutics, Inc.

Kiniksa Pharmaceuticals International, plc

ACADIA Pharmaceuticals Inc.

Zai Lab Limited

Insmed Incorporated

Healthcare

Virtus Biotech ETF

BBP Holdings & Sector Breakdown